Exothera and Remedium Partner on Gene Therapy
CDMO Exothera and Remedium Bio have announced a partnership to scale up manufacturing for an osteoarthritis gene therapy candidate. The collaboration highlights a trend of specialized biotech-CDMO partnerships for viral vector production, where process scale-up and digital infrastructure are key differentiators.
- Remedium Bio's lead candidate, AAV2-FGF18, is a single-injection gene therapy for osteoarthritis designed to reverse cartilage loss. It is based on the clinically proven anabolic mechanism of Fibroblast Growth Factor 18 (FGF18). The collaboration with Exothera will focus on developing a high-yield, suspension-based manufacturing process using a HEK-293 cell line to reduce the cost of goods. - Exothera, a Univercells company, will leverage its exoREADY platform for the process development. The company utilizes innovative manufacturing technologies like the scale-X fixed-bed bioreactor and the NevoLine upstream platform, which are designed for intensified, scalable, and cost-effective viral vector production. - The gene therapy CDMO market is experiencing tension; while the market size was valued at $8.07 billion in 2025 and is projected to grow, a post-2021 capital pullback in the biotech sector has led to underutilization of the rapidly expanded manufacturing capacity. This has caused some CDMOs to step back from specialization, creating challenges for developers seeking specific capabilities. - A major technical hurdle in scaling viral vector manufacturing is the transition from traditional, labor-intensive adherent cell culture methods to more scalable suspension culture systems. Key challenges include managing the ratio of full to empty capsids, which impacts product efficacy, and improving downstream processing to increase product recovery. - To address manufacturing complexities, the industry is increasingly adopting digital tools. Digital twins are being used to simulate and optimize bioprocesses, predict outcomes, and reduce variability before physical implementation, connecting data from systems like LIMS and MES for a unified view of performance. - AI and machine learning are being applied to optimize process parameters, with some CDMOs reporting up to a 50% increase in productivity by fine-tuning factors like seeding densities based on models trained on GMP batch data. These technologies are also used to enhance viral vector design and streamline the creation of regulatory documents. - Remedium Bio, founded in 2020, has raised a total of $3.5 million over five funding rounds. The company's Prometheus™ platform is designed to be a dose-adjustable gene therapy system applicable to a range of diseases, including diabetes and stroke, beyond its lead osteoarthritis candidate. - Exothera operates a large-scale 8,600 m² (92,570 ft²) viral vector facility in Jumet, Belgium, which includes 2,100 m² (22,600 ft²) of GMP-certified manufacturing space. The facility is equipped for both adherent and suspension platforms with bioreactor capacities up to 2,000L.
